Stroke; a journal of cerebral circulation
-
Randomized Controlled Trial Multicenter Study Comparative Study
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Intracranial hemorrhage (ICH) is a life-threatening complication of anticoagulation. ⋯ Among patients with atrial fibrillation treated with anticoagulation, the risk of ICH was higher among Asians, blacks, the elderly, and in those with previous stroke or transient ischemic attack, increased diastolic blood pressure, and reduced platelet count or serum albumin at baseline. The risk of ICH was significantly lower in patients with heart failure and in those who were randomized to rivaroxaban instead of warfarin. The external validity of these findings requires testing in other atrial fibrillation populations.
-
Review Meta Analysis
Cognitive impairment and risk of stroke: a systematic review and meta-analysis of prospective cohort studies.
Cognitive impairment is linked to vascular risk factors and brain vascular pathologies. Several studies have tested whether subjects with cognitive impairment have higher risk for stroke. The aim of this study was to systematically review available evidence on the association between cognitive impairment and risk of stroke to obtain precise effect estimates of the association and to identify which cognitive domains associate most with incident stroke. ⋯ Cognitive impairment is associated with higher risk of stroke. The associations were not significantly different for executive function, memory, and language.
-
Randomized Controlled Trial Comparative Study
Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience.
Interventional Management of Stroke (IMS) III is a randomized, parallel arm trial comparing the approach of intravenous tissue-type plasminogen activator followed by endovascular treatment with intravenous tissue-type plasminogen activator alone in patients with acute ischemic stroke presenting <3 hours of symptom onset. The trial intended to enroll 900 subjects to ensure adequate statistical power to detect an absolute 10% difference in the percentage of subjects with good outcome, defined as modified Rankin Scale score of 0 to 2 at 3 months. In April 2012, after 656 subjects were randomized, further enrollment was terminated by the National Institute of Neurological Disorders and Stroke based on the prespecified criterion for futility using conditional power<20%. ⋯ http://www.clinicaltrials.gov. Unique identifier: NCT00359424.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial.
About one half of those who develop adult-onset moyamoya disease experience intracranial hemorrhage. Despite the extremely high frequency of rebleeding attacks and poor prognosis, measures to prevent rebleeding have not been established. The purpose of this study is to determine whether extracranial-intracranial bypass can reduce incidence of rebleeding and improve patient prognosis. ⋯ http://www.umin.ac.jp/ctr/index.htm. Unique identifier: C000000166.
-
Randomized Controlled Trial Multicenter Study
Early intensive versus minimally invasive approach to postoperative hemodynamic management after subarachnoid hemorrhage.
The results of previous studies suggest that early goal-directed fluid therapy (EGDT) reduces delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage, but the effects of EGDT on clinical outcomes are still unclear. This study aimed to determine whether EGDT improves outcomes compared with standard less-invasive hemodynamic therapy. ⋯ http://www.clinicaltrials.gov. Unique identifier: UMIN000007509.